Myeloproliferative Neoplasm Clinical Trials

80 recruitingLast updated: June 17, 2026

There are 80 actively recruiting myeloproliferative neoplasm clinical trials across 31 countries. Studies span Phase 2, Phase 1, Not Applicable, Phase 3, Early Phase 1. Top locations include Houston, Texas, United States, Boston, Massachusetts, United States, New York, New York, United States. Updated daily from ClinicalTrials.gov.


Myeloproliferative Neoplasm Trials at a Glance

80 actively recruiting trials for myeloproliferative neoplasm are listed on ClinicalTrialsFinder across 6 cities in 31 countries. The largest study group is Phase 2 with 33 trials, with the heaviest enrollment activity in Houston, Boston, and New York. Lead sponsors running myeloproliferative neoplasm studies include M.D. Anderson Cancer Center, Fred Hutchinson Cancer Center, and Incyte Corporation.

Browse myeloproliferative neoplasm trials by phase

Treatments under study

About Myeloproliferative Neoplasm Clinical Trials

Looking for clinical trials for Myeloproliferative Neoplasm? There are currently 41 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Myeloproliferative Neoplasm trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Myeloproliferative Neoplasm clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 80 trials

Recruiting
Phase 2

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

Acute Myeloid LeukemiaMyelodysplastic SyndromeAcute Myeloid Leukemia Post Cytotoxic Therapy+2 more
National Cancer Institute (NCI)2,000 enrolled347 locationsNCT05564390
Recruiting
Phase 2

Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients With High-Risk Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)

Acute Myeloid LeukemiaAcute Myeloid Leukemia Post Cytotoxic TherapyAcute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm+1 more
National Cancer Institute (NCI)335 enrolled221 locationsNCT05554406
Recruiting
Phase 2

CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Myelodysplastic SyndromeMyeloproliferative NeoplasmRecurrent Acute Myeloid Leukemia+2 more
M.D. Anderson Cancer Center30 enrolled1 locationNCT04493164
Recruiting
Phase 1

A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms

Primary myelofibrosis (PMF)Post-polycythemia Vera MyelofibrosisPost-essential Thrombocythemia Myelofibrosis+3 more
Prelude Therapeutics100 enrolled5 locationsNCT07469891
Recruiting

Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution

Diffuse Large B Cell LymphomaHodgkin LymphomaNon-Hodgkin Lymphoma+16 more
Children's Hospital Medical Center, Cincinnati30 enrolled5 locationsNCT06131801
Recruiting
Phase 1Phase 2

Phase 1/ Phase 2 Study to Assess Safety and Efficacy of Orally Administered JBI-802 in Subjects With Myeloproliferative Neoplasms (MPN) and Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) With Thrombocytosis

Myeloproliferative Neoplasms (MPN)Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN)Essential Thrombocythemia, ET
Jubilant Therapeutics Inc.30 enrolled7 locationsNCT07612280
Recruiting
Early Phase 1

Hyperbaric Oxygen Therapy and Allogeneic Peripheral Blood Stem Cell (PBSC) Transplant

Acute Myeloid LeukemiaMyelodysplastic SyndromesChronic Myelomonocytic Leukemia+4 more
Omar Aljitawi24 enrolled1 locationNCT03964506
Recruiting
Phase 1

Study of INCA036978 in Participants With Myeloproliferative Neoplasms

Myeloproliferative Neoplasms
Incyte Corporation218 enrolled49 locationsNCT07441694
Recruiting
Not Applicable

Evaluation of Optical Genome Mapping in Phi Negative Myeloproliferative Neoplasia in the Detection of Acquired Cytogenetic Abnormalities

Myeloproliferative NeoplasmPrognostic StratificationOptical Genome Mapping+2 more
Centre Hospitalier Universitaire, Amiens300 enrolled1 locationNCT05714592
Recruiting
Phase 3

A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials

Beta-ThalassemiaMyelodysplastic Syndromes (MDS)Myeloproliferative Neoplasm(MPN)-Associated Myelofibrosis
Celgene665 enrolled143 locationsNCT04064060
Recruiting

Evaluation of the Pathobiology of CALR-mutated MPN Cells

Myeloproliferative Neoplasm
Wake Forest University Health Sciences35 enrolled2 locationsNCT06480591
Recruiting
Phase 2

Personalized NK Cell Therapy in CBT

Acute Lymphoblastic LeukemiaMyelodysplastic SyndromeChronic Myelomonocytic Leukemia+23 more
M.D. Anderson Cancer Center100 enrolled1 locationNCT02727803
Recruiting
Phase 2

Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers

Acute Myeloid LeukemiaMyeloproliferative NeoplasmBlast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive+4 more
M.D. Anderson Cancer Center100 enrolled1 locationNCT03589729
Recruiting
Phase 2

A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)

Myelodysplastic/Myeloproliferative NeoplasmPolycythemia VeraPrimary Myelofibrosis+5 more
National Cancer Institute (NCI)62 enrolled31 locationsNCT06661915
Recruiting
Phase 2

Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant

Acute Lymphoblastic LeukemiaAcute LeukemiaMyeloproliferative Neoplasm+14 more
Fred Hutchinson Cancer Center68 enrolled10 locationsNCT03779854
Recruiting

Identification of MPN-specific Antigens and Anti-MPN TCRs in Myeloproliferative Neoplasm

Primary myelofibrosis (PMF)Essential Thrombocythemia, ETMyeloproliferative Neoplasm (MPN)+1 more
Université Catholique de Louvain150 enrolled1 locationNCT07590986
Recruiting
Phase 1

Phase Ib Study of CD33 FPBMC in Patients With MRD+ AML or MDS

Acute Myeloid LeukemiaMyelodysplastic SyndromesMyelodysplastic/Myeloproliferative Neoplasm
University of Virginia23 enrolled1 locationNCT07270978
Recruiting

Project: Every Child for Younger Patients With Cancer

Malignant Solid NeoplasmNeuroendocrine NeoplasmCentral Nervous System Neoplasm+15 more
Children's Oncology Group75,000 enrolled278 locationsNCT02402244
Recruiting
Phase 1

A Study to Evaluate the Safety, Tolerability of INCB160058 in Participants With Myeloproliferative Neoplasms

Myeloproliferative Neoplasms
Incyte Corporation186 enrolled30 locationsNCT06313593
Recruiting
Phase 1

Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.

Acute Myeloid LeukemiaChronic Lymphocytic LeukemiaNon-Hodgkin Lymphoma+10 more
Newave Pharmaceutical Inc100 enrolled8 locationsNCT04771572